Trial Profile
Expanded access study of iodine-131 anti-B1[Iodine-131-tositumomab] antibody for relapsed/refractory low-grade and transformed low-grade non-Hodgkin's lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Jul 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Corixa Corp
- 27 Nov 2006 New trial record.